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Mutations in ZDHHC9, Which Encodes a Palmitoyltransferase of
NRAS and HRAS, Cause X-Linked Mental Retardation Associated
with a Marfanoid Habitus
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We have identiﬁed one frameshift mutation, one splice-site mutation, and two missense mutations in highly conserved
residues in ZDHHC9 at Xq26.1 in 4 of 250 families with X-linked mental retardation (XLMR). In three of the families,
the mental retardation phenotype is associated with a Marfanoid habitus, although none of the affected individuals
meets the Ghent criteria for Marfan syndrome. ZDHHC9 is a palmitoyltransferase that catalyzes the posttranslational
modiﬁcation of NRAS and HRAS. The degree of palmitoylation determines the temporal and spatial location of these
proteins in the plasma membrane and Golgi complex. The ﬁnding of mutations in ZDHHC9 suggests that alterations in
the concentrations and cellular distribution of target proteins are sufﬁcient to cause disease. This is the ﬁrst XLMR gene
to be reported that encodes a posttranslational modiﬁcation enzyme, palmitoyltransferase. Furthermore, now that the
ﬁrst palmitoyltransferase that causes mental retardation has been identiﬁed, defects in other palmitoylation transferases
become good candidates for causing other mental retardation syndromes.
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Mental retardation is the clinical description of difﬁculties
with intellectual processing. The underlying cellular ab-
normalities that cause this phenotype are enormously var-
iable, and the term “mental retardation” reﬂects a ﬁnal,
common description of multiple, complex processes in
brain development and sustained function. Mental retar-
dation may occur if neuronal numbers are reduced early
in embryogenesis due to a failure of appropriate cell di-
vision, as in microcephaly,1,2 or if there is failure of neural
migration.3,4 Also, abnormalities of the structural com-
ponents of the synapse will affect the speed and accuracy
of sustained neural processing,5,6 and several transcription
factors7,8 and members of the guanosine triphosphastase
protein signaling cascades have also been identiﬁed as
causing mental retardation.9,10
To identify novel genes that cause X-linked mental re-
tardation (XLMR), we have embarked on a systematic
screen for mutations in genes on the X chromosome. We
have collected and characterized a cohort of 250 families
in which at least two males in the family have mental
retardation as the predominant clinical phenotype and in
which there was no known molecular diagnosis. All fam-
ilies have been examined and have no abnormalities by
conventional karyotype analysis at 500 G-banding reso-
lution. DNA from probands from the families have been
screened and are negative for mutations in 61 known syn-
dromic and nonsyndromic XLMR genes by sequence anal-
ysis of the coding exons and splice junctions. Expansions
of the FMR1 trinucleotide repeat were also excluded. Al-
though all families have mental retardation as the pre-
dominant feature, some families also had both consistent
and inconsistent additional clinical abnormalities, such as
macrocephaly, short stature, and spasticity. These features
were recorded but were not used as selection criteria for
screening. DNA from an affected individual from each
family was screened for variants in the coding exons and
splice junctions of the remaining 676 Vega-annotated X-
chromosome genes (Vega Genome Browser) by bidirec-
tional, PCR-based direct sequencing.
Two truncating and two missense mutations were
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Figure 1. Pedigrees of families with XLMR and mutations in ZDHHC9. Individuals marked with an asterisk (*) carry the mutant allele
in each family. Carrier females who have been shown to be heterozygous for the wild-type allele and the mutation are labeled “het.”
Representative sequence chromatograms of wild-type and mutant sequences are shown below each pedigree. n.a. p no sample was
available for testing; wt p wild-type sequence.
found in the zinc ﬁnger, DHHC-type containing 9 gene
(ZDHHC9 [GenBank accession number NM_016032]), lo-
cated in Xq26.1. In family 152, there is a 4-bp duplication,
c.172_175dup (p.Y59fsX33), present in two brothers and
their mother (ﬁg. 1). The maternal uncle of the brothers,
who was also affected, was unavailable for analysis. In
family 602, a splice-site mutation, c.1675GrC, was de-
tected in two affected brothers and their mother and was
absent from an unaffected brother. In silico analysis of the
splice-site variant c.1675GrC by use of NNSPLICE
(BDGP: Splice Site Prediction by Neural Network) predicts
the reduction of the strength of the splice-donor site from
76.46% to 62.23% . This was conﬁrmed by sequence anal-
ysis of ZDHHC9 cDNA, prepared from lymphocytes from
the proband and ampliﬁed using PCR primers situated
within exons 2 and 4 (table 1). The transcript identiﬁed
was abnormal and used an upstream splice-donor site
(consensus strength 76.82%) within exon 2, resulting in
a frameshift and protein truncation, T11fsX33 (ﬁg. 2). In
families 031 and 576, missense variants were identiﬁed.
In family 031, c.442CrT (p.R148W) was detected in two
brothers and their mother. In family 576, the variant
c.448CrT (p.P150S) was found in four affected males (ﬁg.
1). We evaluated the potential effects of these missense
variants on ZDHHC9 function by comparing amino acid
conservation at these positions in paralogs and orthologs
within and across species (ﬁg. 3). Both R148 and P150 are
conserved from man to yeast in the context of only 31%
total amino acid identity in ZDHHC9 between these two
species (blastp [NCBI BLAST Web site]). Moreover, they
reside within a larger block of 52 aa residues that are highly
conserved and form the active site of the palmitoyltrans-
ferase enzyme (ﬁgs. 3 and 4). Comparison of paralogs of
ZDHHC9 in humans show that the residues equivalent to
R148 and P150 in ZDHHC14, ZDHHC5, ZDHHC18,
ZDHHC8, and ZDHHC19 are also conserved (ﬁg. 3). In
the remaining 18 human paralogs, these residues are not
universally conserved, but these paralogs are themore dis-
tantly related proteins. Conservation across species shows
that these residues are conserved in ZDHHC14 and
ZDHHC5 in D. rerio and in the only two paralogs of the
ZDHHC family in C. elegans (ﬁg. 3). The conservation of
these amino acids and their positionwithin a known func-
tional domain of the protein indicate that they signiﬁ-
cantly inﬂuence ZDHHC9 function and, therefore, that
these missense variants are likely to be disease causing (ﬁg.
4). No other variants in ZDHHC9 were detected in the
250-case series. The four sequence variants were not de-
tected in DNA from 445 normal control samples, which
represent 667 X chromosomes. Furthermore, no addi-
tional common or rare coding sequence variants were de-
tected in the control series, demonstrating that ZDHHC9
shows little variation in unaffected individuals. Details of
PCR primers and sequencing temperatures are given in
table 1.
The presenting phenotype in the four families wasmod-
erate mental retardation in two or more males. In three
families (602, 031, and 576) a diagnosis of XLMR with a
Marfanoid habitus or Marfan syndrome was considered.
Although the physique of the affected individuals was
generally a long and thin habitus, none met the Ghent
criteria for Marfan syndrome.11 In family 152, FG syn-
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Table 1. Primers Used for PCR Ampliﬁcation of ZDHHC9
Segment
Primer Sequence
(5′r3′)
Forward Reverse
Exon 2 ACCCAGCGGCAGGAATAG CAGCCCCAAATCAGTACTACAAA
Exon 3 TGTATGTTATAGGTGGCAGCAGT CAGGATCTCAGAGAGAAAAGGC
Exon 4 TGCATGCACTTAGTGGAGTTTT GATTTGCAGTTTTTCAGGAGC
Exon 5 TTACAACTGAAATAGACAATGATCCTG ACCAGTAATTATGGCCCCAGT
Exon 6 GATGAGGCTCTTCACCCTTG ATGAAGAACTGGTGGGGGA
Exon 7 ATGGAAACATGGCTTTTTGTG GAGGCACCAGCTAGCCTTTA
Exon 8a GCAGATCAAAGGATCATGGA AGAGAGTTAACAAAGAACTGGGC
Exon 9 GACATTTCCTGGTTTGTGGA AAATCTTAATCTACATCAAGGACACA
Exon 10 TTCAGTTGTGTTCTGCCGAG CTTCTGCCACTGCCTTGAGT
cDNA 2–4 ACCCAGCGGCAGGAATAG GGAAGATCTTGCATGTGTAACAG
a Primer was placed in the coding sequence because of ﬂanking intronic repeats.
Figure 2. a, RT-PCR analysis of the ZDHHC9 gene by use of lymphocyte RNA from an affected male individual in family 602 and an
unaffected control. A 547-bp PCR product was identiﬁed from cDNA made from control cells containing sequence from exons 2–4, by
use of the predicted splice junctions. In family 602, only a 407-bp PCR product was identiﬁed. b, Diagram of the cDNA detected in
family 602, which included an upstream splice-donor site, resulting in the loss of 140 bp at the terminus of exon 2, and the sequence
chromatogram of the novel splicing event, leading to the mutation. c, Effect of the upstream splice-donor site within exon 2 spliced
to exon 3. This results in a frameshift and truncated protein p.T11fsX33.
drome was brieﬂy considered for the diagnosis but was
dismissed. The physique was not Marfanoid in this family
either.
In family 152, the uncle was said to be profoundly re-
tarded and unable to walk or talk and needed full-time
care. His problems were attributed to birth injury, because
the umbilical cord was around his neck at birth. No other
details are available. The two sibling nephews were re-
ferred when they were 6 and 4 years old, respectively,
because both boys had developmental delay andmoderate
learning disability. The ﬁrst child was born at term by
elective cesarean delivery due to failure of progressiondur-
ing labor, but he did not require admission to a special-
care baby unit after delivery. His birth weight was 3.4 kg.
A solitary juvenile xanthogranuloma appeared at age 4 wk
and disappeared at age 15 mo. Developmental delay was
noted at age 8 mo, since the child was ﬂoppy and not
sitting. He was not walking at age 18 mo, and speech and
language were delayed. At age 6 years, his heightwas 111.8
cm (50th percentile), and his weight was 20.3 kg (25th
percentile). His head circumference was 52.5 cm (75th per-
centile). A clinical diagnosis of FG syndrome was consid-
ered because of the presence of hypotonia, a cowlick, and
a high forehead but, in the absence of macrocephaly, se-
vere constipation, and hypertelorism, this clinical diag-
nosis was deemed unlikely. The clinical features of the
second child were similar to those of the older brother,
but the developmental progression was slower. His birth
weight was 3.2 kg, and his growth parameters at age 4
years were the 25th percentile for height, the 75th per-
centile for weight, and the 75th percentile for head cir-
cumference. Results of metabolic investigations, including
white blood cell enzymes, urine organic acids, very-long-
chain fatty acids, and creatine kinase levels, were all
normal.
In family 602, two brothers presented with develop-
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Figure 3. Sequence alignment of the conserved palmitoyltransferase active site of proteins ZDHHC9, ZDHHC14, and ZDHHC5 in multiple
species (Homo sapiens, Canis familiaris, Mus musculus, Gallus gallus, Danio rerio, Xenopus laevis, Tetraodon nigroviridis, Drosophila me-
lanogaster, Caenorhabditis elegans, Neurospora crassa, and Saccharomyces cerevisiae). Sequence alignment was performed using ClustalW.
Conserved amino acid residues are highlighted in yellow, and the two missense mutations are identiﬁed in red.
Figure 4. a, Diagrammatic representation of the exon structure
of ZDHHC9, with positions of mutations found in families with
XLMR. Exons that are translated are indicated by yellow shading.
b, Diagrammatic representation of the protein ZDHHC9, with the
palmitoyltransferase domain indicated by green shading. The lo-
cation of the amino acid changes in the protein due to mutations
in ZDHHC9 are indicated by arrows. The family numbers are in
parentheses.
mental delay. The older brother was delivered at term after
an elective cesarean delivery at 42 wk gestation, and his
birth weight was 4.2 kg. He walked at age 3 years 6 mo
and developed limited speech at age 4 years 6 mo. At age
13 years, a diagnosis of Marfan syndrome was considered.
His head circumference was 58 cm (197th percentile),
height was 178 cm (90th–97th percentile), arm span was
190 cm (span:height ratio 1.06), and upper:lower segment
ratio was 0.93. Additional clinical features were pectus car-
inatum, pes planus, and arachnodactyly. Although he had
at least two major skeletal features of Marfan syndrome,
the results of eye examination and cardiac echocardio-
gram were normal. Additional investigations excluded
homocystinuria and other metabolic diseases. The youn-
ger affected brother is a DZ twin and had similar features
to the older affected brother, including pectus carinatum,
pes planus, and thin facial features. The younger brother’s
height was in the 75th–90th percentile, his arm span:
height ratio was 1.0, and his upper:lower segment ratio
was 0.96. In adulthood, the younger affected brother has
developed major behavioral problems, and a diagnosis of
schizophrenia has been made. He receives medication in
a supported environment. The unaffected twin is intel-
lectually normal and does not have a Marfanoid habitus.
In family 031, two brothers presented with develop-
mental delay and mental retardation with unremarkable
birth histories. They were described as having Marfanoid
features. The older brother’s birth weight was 3.2 kg, and
he was a slow feeder, sat at age 13 mo, walked at age 3
years, and talked at age 4 years. He attended a special
school and lives semi-independently in a supervised
home. As an adult, his head circumference is 55.5 cm (9th–
25th percentile), his height is 169.5 cm (9th–25th percen-
tile), and his arm span is 173.5 cm (span:height ratio
1.02), with mild ﬁxed ﬂexion deformity at the elbows. The
younger brother has similar facial features, with large ears,
long ﬁngers and toes, and pes planus, and has similar
growth and developmental parameters. His birth weight
was 3.5 kg, and, at age 16 years, his height was 172.4 cm
(25th percentile), his arm span was 176 cm (span:height
ratio 1.02), and his head circumference was 57.6 cm (50th
percentile).
In family 576, the proband was referred to a genetics
service because of joint hypermobility, pectus excavatum,
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long mobile digits, and delayed sitting at age 12 mo. Preg-
nancy and delivery were uncomplicated, but the child pre-
sented with pyloric stenosis at age 6 wk. Adducted thumbs
were noted shortly after birth but gradually resolved spon-
taneously by age 14 mo. At age 14 mo, the child had a
long face, strabismus, and prominent ears that were not
crumpled. His palate was normal and not high, and ex-
amination of the spine showed that it was normal, with
no evidence of kyphoscoliosis. Long, thin limbs were
noted, with long digits, 5th-ﬁnger camptodactyly, and
long toes with camptodactyly. His height was in the 90th–
98th percentile, his weight was !50th percentile, and his
head circumference was in the 50th–75th percentile. A
clinical diagnosis of XLMR and Marfanoid habitus was
made on the basis of the family history. The mother of
this boy reported that her brother had a similar physique,
was tall and thin, was double-jointed, and had similarly
unusual hands. He also has signiﬁcant learning difﬁculties
and has managed little employment. She also has two
maternal cousins who are affected. In summary, the clin-
ical phenotype in the four families is one of hypotonia,
signiﬁcant delay in walking disproportionate to the in-
tellectual disability, and a Marfanoid habitus in some
individuals.
ZDHHC9 (GenBank accession number NP_057116) is an
integral membrane protein of 364 aa containing four pre-
dicted transmembrane spans, a proline-rich domain, and
a zinc-ﬁnger DHHC (aspartic acid–histidine-histidine-cys-
teine) domain in the cytoplasmic loop. It is a palmitoyl-
transferase that catalyzes the posttranslational modiﬁca-
tion of RAS.12 The ZDHHC9 gene is expressed highly in
kidney, skeletal muscle, brain, lung, and liver; to a lesser
extent in placenta, heart, colon, and small intestine; and
at low levels in peripheral blood cells, thymus, and
spleen.12 ZDHHC9 forms a complex with GCP16 and co-
localizes in the Golgi apparatus when overexpressed in
mammalian cells. This complex palmitoylates HRAS and
NRAS and not GAP-43 or Gai1.
12 There may be additional
target proteins modiﬁed by ZDHHC9, but they have not
been identiﬁed thus far. In mammalian cells, palmitoy-
lation determines both the temporal and spatial locali-
zation of NRAS and HRAS.13 KRAS is not subject to post-
translational modiﬁcation by palmitoyltransferase and is
mainly identiﬁed at the plasma membrane. Monopalmi-
toylated NRAS displays a more pronounced Golgi locali-
zation, a faster retrograde plasma membrane to Golgi traf-
ﬁcking, and a several-fold shorter time at the plasma
membrane, comparedwith the dually palmitoylatedHRAS
species.13,14
Recently abnormalities in HRAS and KRAS have been
identiﬁed in Costello syndrome (MIM 218040), cardiofa-
ciocutaneous syndrome (MIM 115150), and Noonan syn-
drome (MIM 163950), suggesting that changes in these
and other molecules in the RAS–mitogen-activated
protein (MAP) kinase pathway can cause signiﬁcant de-
velopmental abnormalities.15–18 Interestingly, these syn-
dromes are associated with a mental retardation pheno-
type, providing further evidence of the role of this
pathway in intellectual processing. The mechanism by
which loss-of-function mutations in ZDHHC9 cause men-
tal retardation is unclear, but it may be through alteration
of the relative proportion of the RAS proteins within the
different compartments of nerve cells. This may result in
alterations in the growth and development characteristics
of neurons similar to those seen by alteration of palmi-
toylation of GAP-43 and PSD-95.19,20 Palmitoylation of
PSD-95, a major component of the postsynaptic density,
is required for postsynaptic targeting and clustering of glu-
tamate receptors and palmitoylation ofGAP43 is sufﬁcient
to alter the branching of dendrites and axons in hippo-
campal neurons. The ﬁnding of mutations in ZDHHC9
therefore adds a further layer of complexity to our un-
derstanding of the mental retardation phenotype, as it
suggests that alterations in the concentrations and cellular
distribution of normal proteins is sufﬁcient to cause
disease.
Our ﬁndings provide further support for the importance
of RAS signaling in the development of intellectual pro-
cessing. Furthermore, now that the ﬁrst palmitoyltrans-
ferase that causes mental retardation has been identiﬁed,
defects in other palmitoylation transferases become good
candidates for causing other forms of X-linked or auto-
somal forms of mental retardation.19,20
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